Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects

Clinical Therapeutics

Volumn 36, Issue 11, 2014, Pages 1638-1649

  Boinpally, Ramesh ^a   Gad, Nayra ^a   Gupta, Samir ^a   Periclou, Antonia ^a  

^a FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Carbamazepine; CYP3A4; Depression; Ketoconazole; Pharmacokinetics; Vilazodone

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME P450 3A4; KETOCONAZOLE; VILAZODONE; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; FEMALE; FLATULENCE; FOLLOW UP; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL INSTABILITY; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; STEADY STATE; SUICIDAL BEHAVIOR; URTICARIA; VOMITING; ADOLESCENT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; MAJOR DEPRESSION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; CARBAMAZEPINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A INDUCERS; CYTOCHROME P-450 CYP3A INHIBITORS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; VILAZODONE HYDROCHLORIDE; YOUNG ADULT;

EID: 84911929764     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.08.003     Document Type: Article

References (13)

1. Forest Pharmaceuticals Inc. Viibryd® (vilazodone hydrochloride) tablets: U.S. Prescribing Information. St. Louis, MO: Forest Pharmaceuticals, Inc.; December 2012.
2. Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs. 2011;25:615-627.
3. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72:441-447.
4. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:326-333.
5. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31:643-646.
6. Boinpally R, Alcorn H, Adams MH, et al. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin Drug Investig. 2013;33:199-206.
7. Longstreth J, Alcorn H, Swan SK, Adams MH, Reed CR. Vilazodone pharmacokinetics in subjects with mild to moderate hepatic impairment. Poster presented at: the 163rd Annual Meeting of the American Psychiatric Association; May 22-26, 2010; New Orleans, Louisiana.
8. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed April 17, 2013.
9. Fromtling RA. Overview of medically important antifungal azole derivatives. Clinical Microbiol Rev. 1988;1:187-217.
10. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003;43:443-469.
11. Bertilsson L, Tybring G, Widen J, et al. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997;44:186-189.
12. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.
13. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 2001;41:535-567.